Research programme: intravenous GAD - Mertiva

Drug Profile

Research programme: intravenous GAD - Mertiva

Alternative Names: GAD 67; GAD65 intravenous - Diamyd Medical; rhGAD65 intravenous - Diamyd Medical

Latest Information Update: 30 Apr 2013

Price : $50

At a glance

  • Originator Mertiva
  • Class
  • Mechanism of Action Enzyme modulators; GABA modulators; Glutamate decarboxylase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Epilepsy; Movement disorders; Stiff-person syndrome

Most Recent Events

  • 30 Apr 2013 No development reported - Preclinical for Stiff-person syndrome in USA (IV)
  • 30 Apr 2013 No development reported - Preclinical for Movement disorders in USA (IV)
  • 30 Apr 2013 No development reported - Preclinical for Epilepsy in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top